Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KRAS inhibitor

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

UCB-Amgen pull development of drug to heal fractures

But romosozumab remains on course in postmenopausal osteoporosis

- PMLiVE

Amgen profits down on rising costs

R&D and general operating expenses cancel out rise in product sales

- PMLiVE

Amgen’s Aranesp disappoints in heart failure

Red blood cell stimulator no better than placebo

- PMLiVE

Amgen invests $200m in Singapore monoclonal antibody facility

New manufacturing plant will produce both clinical and commercial products

- PMLiVE

Amgen signs $180m nanotechnology cancer deal

Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug

- PMLiVE

Amgen offers $762m to end Aranesp lawsuits

Pleads guilty to illegal marketing of anaemia drug

- PMLiVE

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

- PMLiVE

Amgen continues spending spree, acquires deCode Genetics

Will pay $415m for Icelandic genetic information firm

- PMLiVE

Astellas seeks FDA approval for personalised Tarceva in lung cancer

Application supported by Roche's EGFR companion diagnostic test

Amgen’s Joseph Turgeon joins Spectrum as SVP sales and commercial operations

Joins fellow former Amgen employee Ken Keller

- PMLiVE

Amgen buoyant as profits rise in Q3

Increases 2012 revenue and earnings forecasts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links